{‘She lacks zero qualifications’: this American healthcare establishment braces for Høeg's role at the Food and Drug Administration.

While America proceeds with historic changes to its vaccine schedules, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by questioning COVID-19 vaccinations in the pandemic and has focused upon alleged deaths following Covid immunization in her recent position at the FDA.

Scheduled Changes to Pediatric Immunization Program

Agency leaders had intended to unveil sweeping changes to the pediatric immunization program in December, synchronizing the US with the Danish vaccine program, it is understood – a major change that would place the US out of alignment with much of the global community with insufficient data for benefit. The planned update has been postponed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is listed to speak at the gathering. She was recently named interim head of the FDA’s CDER, the fifth person to run the center this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Prasad solidify control at the regulatory agency – and it signals a renewed priority upon dismantling long-standing immunizations at the FDA.

Høeg has frequently advocated for ending specific pediatric shot schedules in the US so as to align more in line with Denmark's approach, a society with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

In her initial comments, she has kept her attention on immunizations – traditionally the purview of Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Qualifications

Høeg has no obvious background in pharmaceutical research, regulation or administrative roles, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She has no expertise in running a large organization. She has no expertise in pharmaceutical oversight.”

Former directors of CBER would “grasp regulatory frameworks and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that former directors who led CBER have had.”

CDER has an immense workload at the FDA, she pointed out.

“Everybody just pays attention on the new drug program, but the generic drug division clears a multitude of generic medications. There’s a biosimilars division, OTC medication office and so forth, and every single one need to be supervised,” Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the position, which manages over 5,000 employees. “It is a huge management job, if you perform it correctly,” the former official added.

Agency Reaction and Controversial Programs

When asked about concerns about Høeg’s credentials and whether this selection indicates greater collaboration among agency officials on immunizations, a spokesperson stated that the “questions rely on flawed presumptions”.

“This background aligns with the duties of her role,” the official stated, citing the time Dr. Høeg spent advising the agency head on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial expedited therapy clearance system that reportedly troubled her former heads. “By what process are these medications being chosen for this fast-track system? Who makes the calls?” Howard said. “There is a lot of confidentiality going on at the agency right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards more relaxed regulations of most medications, with the exception of immunizations.”

Public History on Vaccines

Concerning immunizations, Høeg has a more documented, if problematic, history, Howard observe. She authored a analysis using unverified volunteer-provided data to assess the incidence of heart inflammation after Covid vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the new federal leadership encompassed altering regulations for new vaccines and halting “unnecessary” vaccines, she remarked after the election on a online show. At the FDA, Dr. Høeg has reportedly proposed preventing young men from obtaining Covid vaccinations.

“She’s an thorough true believer who starts off with her conclusions and works backwards to retrofit the data in a extremely deceptive, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow dissenters, {like|